BPC-157 Testing

Mechanism of action

Body Protection Compound-157 is a partial sequence of gastric juice 'BPC' protein. Mechanisms studied include modulation of nitric-oxide pathways, upregulation of VEGFR-2 expression (angiogenic effects), enhanced fibroblast activity, and protection of dopaminergic and serotonergic systems. The vast majority of published work is rodent.

Sequence & structure

Sold as acetate or arginate salt. Arginate is more soluble and stable in injectable preparations; acetate is more common in research vials.

Research areas

• ●Tendon and ligament healing
• ●GI ulcer healing (the original indication)
• ●CNS protection (rodent)
• ●Vascular and wound healing

Dosing in the literature

Common research dosing in rodents: 10 μg/kg systemically. Human anecdotal use varies widely (200–500 μg/day SC). No human FDA approval; no human PK studies published in peer-reviewed literature.

For research/informational purposes only — not medical advice.

What we test on BPC-157

RP-HPLC purity (UV 214 nm), MS/MS sequence confirmation, counter-ion identification by IC, mandatory LAL endotoxin for any injectable.

Common impurities & failure modes

• Sequence deletions

  Particularly common at the Pro-Pro-Pro stretch — proline coupling is sluggish.

• Deamidation

  No Asn/Gln in the sequence, so deamidation is minimal — a useful identity check (if your 'BPC-157' shows deamidation peaks, it is not BPC-157).

• Wrong salt form

  Vials labeled 'arginate' that test as acetate (and vice versa) are common.

• Endotoxin

  Compounded BPC-157 is one of the worst categories we see for endotoxin contamination — frequently >5 EU/mL when injectable spec is <0.5 EU/mL.

Storage & stability

2–8 °C lyophilized; reconstituted stable ~30 days refrigerated.

Regulatory status

Not FDA-approved for any indication. Removed from FDA bulk-compounding 503A nominations list in 2023.

Frequently asked questions